# OnCo record ml-016 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ml-016/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ml-016" ;
  schema:name "ML-016"@en ;
  schema:alternateName "iNPG-pDox"@en ;
  schema:description "ML-016 is an experimental injectable nanoparticle generator: polymer-doxorubicin conjugate formulated in nanoporous silicon microparticles from BrYet, in phase 1 trials for advanced solid tumours with lung and/or liver involvement."@en ;
  schema:url <https://onco.cc/drugs/ml-016/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://bryetpharma.com/technology/>, <https://bryetpharma.com/technology/>, <https://bryetpharma.com/2026/09/bryet-announces-aifa-approval/>, <https://clinicaltrials.gov/api/v2/studies/NCT07723482>, <https://clinicaltrials.gov/search?intr=ML-016> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Injectable nanoparticle generator: polymer-doxorubicin conjugate formulated in nanoporous silicon microparticles" ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/> ;
  onco:companies <https://onco.cc/companies/bryet/> ;
  onco:trials <https://onco.cc/trials/nct07723482/> .